Shorter Turnaround Time for BRAF Mutation Testing
Obtaining blood biopsies instead of invasive tissue biopsies may be less risky for patients, faster, and cost less.
A recent study published in Molecular Cancer Therapeutics and in an American Association of Cancer Research news release suggests that cell-free DNA from plasma provides an easy and obtainable material for BRAF mutation analysis for diagnostics and response monitoring. Obtaining blood biopsies instead of invasive tissue biopsies may be less risky for patients, faster, and cost less.
Tebentafusp Continues to Demonstrate Benefit in Metastatic Uveal Melanoma
January 4th 2024Results from a long-term analysis of the phase 3 IMCgp100-202 trial indicate that tebentafusp results in better disease control and long-lasting responses in those with HLA-A*02:01–positive, previously untreated metastatic uveal melanoma.
